Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IL-4(38-37)-PE38KDEL treatment results in complete regression of human glioblastoma tumors

Sep. 21, 1998

York Medical's DiaCIM will be administered to cancer patients

Sep. 18, 1998

Techniclone submits phase II TNT protocol to FDA

Sep. 18, 1998

Maxim enters collaborative agreement with BioNative

Sep. 15, 1998

Imutec reports positive phase I/II results for Virulizin

Sep. 7, 1998

New biologic for breast cancer receives advisory committee approval

Sep. 3, 1998

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Sep. 2, 1998

Medarex receives milestone payment from Merck KGaA

Sep. 2, 1998

Techniclone advancing development of Tumor Necrosis Therapy into phase II

Sep. 2, 1998

Pivotal clinical trial data for rituximab published

Aug. 28, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 24, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026